Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted Naltrexone for Dry January
NCT07132177Phase 2Completed
- Sponsor
- Brigham and Women's Hospital
- Start
- Nov 2025
- Primary completion
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of naltrexone in alcohol use disorder (AUD), sponsored by Brigham and Women's Hospital. Primary endpoints: Recruitment feasibility, Retention feasibility and 3 more. Started Nov 2025; status: completed.
02
Drugs
naltrexone
03
Conditions
alcohol use disorder (AUD)
Beyond the preview
Go deeper on NCT07132177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07132177.